Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma

Malignant melanoma is the most deadly skin cancer, associated with rising incidence and mortality rates. Most of the patients with melanoma, treated with current targeted therapies, develop a drug resistance, causing tumor relapse. The attainment of a better understanding of novel cancer-promoting m...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Ther Oncolytics
Prif Awduron: Federico, Aniello, Steinfass, Tamara, Larribère, Lionel, Novak, Daniel, Morís, Francisco, Núñez, Luz-Elena, Umansky, Viktor, Utikal, Jochen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Gene & Cell Therapy 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327877/
https://ncbi.nlm.nih.gov/pubmed/32637583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.06.001
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg